CA3127729A1 - Treatment of patients at risk of rapid progression of osteoarthritis - Google Patents

Treatment of patients at risk of rapid progression of osteoarthritis Download PDF

Info

Publication number
CA3127729A1
CA3127729A1 CA3127729A CA3127729A CA3127729A1 CA 3127729 A1 CA3127729 A1 CA 3127729A1 CA 3127729 A CA3127729 A CA 3127729A CA 3127729 A CA3127729 A CA 3127729A CA 3127729 A1 CA3127729 A1 CA 3127729A1
Authority
CA
Canada
Prior art keywords
pain
joint
cartilage
score
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127729A
Other languages
English (en)
French (fr)
Inventor
Christoph H. Ladel
Hans Guehring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3127729A1 publication Critical patent/CA3127729A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3127729A 2019-02-08 2020-02-07 Treatment of patients at risk of rapid progression of osteoarthritis Pending CA3127729A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19156281.8 2019-02-08
EP19156281 2019-02-08
PCT/EP2020/053214 WO2020161341A1 (en) 2019-02-08 2020-02-07 Treatment of patients at risk of rapid progression of osteoarthritis

Publications (1)

Publication Number Publication Date
CA3127729A1 true CA3127729A1 (en) 2020-08-13

Family

ID=65365897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127729A Pending CA3127729A1 (en) 2019-02-08 2020-02-07 Treatment of patients at risk of rapid progression of osteoarthritis

Country Status (7)

Country Link
US (1) US20220184180A1 (enExample)
EP (1) EP3920959A1 (enExample)
JP (2) JP7671249B2 (enExample)
AU (1) AU2020218844A1 (enExample)
CA (1) CA3127729A1 (enExample)
IL (1) IL285420A (enExample)
WO (1) WO2020161341A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500742C (en) * 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
EA015644B1 (ru) * 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща
WO2012038953A2 (en) * 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
JP6262731B2 (ja) 2012-08-06 2018-01-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー
US9889179B2 (en) * 2014-02-20 2018-02-13 Merck Patent Gmbh FGF-18 compound dosing regimen

Also Published As

Publication number Publication date
WO2020161341A1 (en) 2020-08-13
US20220184180A1 (en) 2022-06-16
JP7671249B2 (ja) 2025-05-01
JP2022519732A (ja) 2022-03-24
IL285420A (en) 2021-09-30
JP2025105692A (ja) 2025-07-10
EP3920959A1 (en) 2021-12-15
AU2020218844A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
US8207115B2 (en) Treatment of cartilage disorders with FGF-18
CN101505787B (zh) 软骨障碍的治疗
US9724388B2 (en) FGF-18 compound dosing regimen
US20250213467A1 (en) Method of Treating Osteoarthritis
US12383603B2 (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
JP7418324B2 (ja) Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー
ES2918250T3 (es) Biomarcadores metabólicos para predecir la capacidad de respuesta al compuesto FGF-18
US20220226433A1 (en) Method to Identify Responders to Osteoarthritis Therapeutics
US20220184180A1 (en) Treatment of patients at risk of rapid progression of osteoarthritis
KR101686271B1 (ko) 인간 변형성 슬관절증의 예방제 및/또는 치료제 및/또는 악화 억제제
CN113164033B (zh) 用于治疗骨关节炎的制剂
US20200222454A1 (en) New therapy for osteoarthritic pain
US20200129588A1 (en) Method of Treating Knee Pain
JP7365478B2 (ja) 治療用組成物
KR20180035911A (ko) Fgf-18 화합물을 포함하는 조합 조성물
HK40053260A (en) Formulation for use in treating osteoarthritis
HK40053260B (zh) 用於治疗骨关节炎的制剂
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK1129852B (en) Treatment of cartilage disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221001

EEER Examination request

Effective date: 20221001

EEER Examination request

Effective date: 20221001

EEER Examination request

Effective date: 20221001

EEER Examination request

Effective date: 20221001